Understanding OCT Angiography From Pathophysiology to Clinical Imaging Bruno Lumbroso, Marco Rispoli, Eric H Souied, Maria Cristina Savastano, Yali Jia, David Huang
INDEX
Note: Page numbers in bold or italic refer to tables or figures, respectively.
A
Abicipar pegol 101
Acute macular neuroretinopathy (AMN) 161-167, 164165
Aflibercept 99
Age-related macular degeneration (AMD) 7, 35, 45, 55, 195
classification 36
drusen in 35 see also Drusen
dry AMD 45
early stages 35, 51
geographic atrophy 35 see also Geographic atrophy (GA)
late stage 35, 35
modifiable risk factors 37, 45
neovascular AMD, OCTA in 55-58, 5659
neovascularization in, quantification of 5-6, 6
nonmodifiable risk factors 37
pathogenesis 36, 45, 46
prevalence 37
type 1 macular neovascularization with 55, 56
type 2 macular neovascularization with 56, 57
AI see Artificial intelligence (AI)
AMD see Age-related macular degeneration (AMD)
American Academy of Ophthalmology classification of retinopathy 131
Angiogenesis 61, 6264
Angioid streaks 103
AngioVue OCTA system Avanti 6
Antialdosterone 118
Anti-vascular endothelial growth factor (anti-VEGF) therapy 55, 99-102, 100, 103
Artifacts 4-5, 5, 6, 13-16
bulk motion 4, 5, 11
flow projection 4, 5, 10, 13-14, 15
signal reduction 14-15, 16
Artificial intelligence (AI) 13
in image analysis 13, 14, 15, 16
B
Best disease 176-178, 189
Bevacizumab 99
Blood-retina barrier (BRB) 23
inner barrier 23
outer barrier 23-24
Branch artery occlusion 155156
Branch retinal vein occlusion (BRVO) 145, 148-154, 153
deep vascular network in 152
Branch venous occlusion 19, 21, 21
Brolucizumab 102
Bruch's membrane 11, 29
lesion 61
opening (BMO) 200
Bulk motion artifacts 4, 5
C
Capillary pores 23
Central retinal vein occlusion (CRVO) 145-148, 146
Central serous chorioretinopathy (CSC) 113-118
imaging 115-116
management 118
neovascularization in 116-118, 117
pathophysiology 113-114
risk factors 114-115
Chorioretinal anastomosis 80-81, 81
Choroid 30, 30, 189
Choroidal neovascularization (CNV) 35, 61, 73, 103 see also Exudative choroidal neovascularization; Nonexudative choroidal neovascularization
activity features 94, 9697, 96-99
age-related macular degeneration and 65
angiogenesis and 61, 6264
angioid streaks and 103
antiangiogenic factors and angiogenic factors 61
arteriogenesis 65
assessment 66
automated CNV detection using artificial intelligence 14, 15
basic mechanism of 61, 65
biomarkers of CNV activity in exudative AMD 62, 65
Bruch's membrane, abnormalities in 61
capillaries density 66
in children 69
in choroid traumatic rupture 104
classification 61, 62
clinical classification 70-71
definition 65
development of 61-65
early evolution after treatment 91, 9192
effect of projection artifacts on 13
exudative 69, 70
features 66
fibrovascular scars 94, 9495, 104
growth 65
indocyanine green (ICG) features 67
in laser photocoagulation scars 104
loops density 67
loops morphology 67
management 99-102, 100
on margin of atrophic areas 104
maturation after 6 months 91-92, 93
morphology in general 66
in multifocal choroiditis 103-104
myopic 121-122, 122, 123
nonexudative 69, 70
perilesional dark halo 68
physiopathology 61
pigment epithelium cells, alteration in 61
quiescent 97-98
recurrences 92-94, 93
retinal scars, causes of 69
structural OCT features 67
subretinal neovascular membranes, causes of 69
treatment 91
type 1 67, 68
type 2 68
type 3 68
type 4 68
type 1 new vessels fluorescein angiography 67
Yves Salomon Cohen chart 100
Choroidal polypoid vasculopathy (PCV) 40
Choroidal vessels layer 192
Choroid of central serous chorioretinopathy (CSCR) 181
CNV see Choroidal neovascularization (CNV)
Conbercept 101
Cones and rods 28, 29
Cone dystrophy 173
Congenital stationary night blindness (CSNB) 189
Convolutional neural network (CNN) 14
Cotton-wool spots (CWS) 160, 161
CSC see Central serous chorioretinopathy (CSC)
Cuticular drusen 41
D
Decorrelation value 3
Deep capillary plexus (DCP) 159, 166
Diabetic macular edema 133, 136-137
Diabetic maculopathy 132
Diabetic retinopathy (DR) 14, 125, 131
future prospective 128-129
inner blood-retinal barrier (BRB) dysfunction in 125
management of 136-143
pathophysiology 125–127, 125-127
proliferative 128
treatment 127-128
Disorganization of retinal inner layers (DRILs) 132, 161
Dome-shaped macula 181
Doyne honeycomb dystrophy 42, 42
Dropout measurement 19
Drusen 35, 39, 40, 51 see also Age-related macular degeneration (AMD)
classification 39-40, 41
cuticular 41
early AMD grading 43
features 51
ghost 42, 42
growth of 39
hard 40, 41
OCT angiography 39
pachydrusen 40, 41
and pseudodrusen 39, 40
reticular 41, 41-42
small 39
soft 40, 41, 52
in type II membranoproliferative glomerulonephritis 42-43, 43
vascularized 42-43 (see also Vascularized drusen)
Dynamic phototherapy 118
E
Electroretinogram (ERG) 173
Ellipsoid zone 28, 35
Epiretinal membrane (ERM) 183, 187
risk factor 183
EPR–photoreceptor complex, genetics of 189
Examination, OCTA 9-11
boundaries control 11
default settings 11
fixation problems 10
machine handling and protocol 9
mistakes to be avoided 10-11
patient positioning 10
practical problems, fixing of 10
skills for 9
technical tips 10
thresholding algorithm 9-10
Extensive retinal ischemia 132
Exudative choroidal neovascularization 69, 70, 73, 94
arcade morphology 74
capillaries density 74
in children 82
evolution 81-83, 82
features 73
loops compactness 74
morphology 74, 75
perilesional dark halo 75, 79, 79
report 74
retinal scars, causes of 82
structural OCT features 75
subretinal neovascular membranes, causes of 81
type 1 new vessels 75-76, 7578
type 1 + 2 new vessels 76
type 2 new vessels 79-80, 80
type 3 new vessels 80-81, 81
type 1 new vessels fluorescein angiography 74
type 1 new vessels indocyanine green features 74
Eye tracker 10
F
Faricimab (Roche) 102
Fibrocellular lesion 55
Fibrotic scar 83, 83, 94, 9495
Flow projections artifacts 4, 5, 10
Fluorescein angiography (FA) 131, 149, 149150
Foveal avascular zone (FAZ) 133
Full-thickness macular hole (FTMH) 184
Fundus autofluorescence 173
Fundus clinical examination 173
G
GA see Geographic atrophy (GA)
Ganglion cell complex (GCC) 27, 28, 195
Ganglion cell layer (GCL) 209
Geographic atrophy (GA) 35, 40, 45, 55
atrophic progression in 45
classification of atrophy 45-47
clinical features 47
cross-section structural OCT in 47, 47, 48
evolution of 49
future perspective 50
OCTA in 47-48, 48
physiopathogenesis 45
prevention and treatment 49-50
silent nonexudative subclinical CNV 48-49, 49
Ghost drusen 42, 42
Glaucoma 195
classification 196
diagnostic approach 198
risk factors 195
H
Henle fibers 25, 26, 27
Hyper-reflective foci 191
I
Indocyanine green (ICG) angiography 181
Inherited retinal dystrophies (IRD) 189
Inner limiting membrane (ILM) 11
Inner retina 191
genetics of 190
Intermediate capillary plexus (ICP) 159, 166
Intraretinal microvascular abnormalities (IRMAs) 133-136
L
Lamina fusca 30
Leber congenital amaurosis (LCA) 189
M
Macular dystrophies 174
Macular edema 192
Macular scar 55
Microaneurysms 132
Micropulse laser 118
Motion artifacts 4, 5, 11
Müller's cells 25, 26
Multifocal choroiditis (MC) 103-104
Multiple sclerosis (MS) 209
Myopia 121
myopic CNV 121-122, 122, 123
neovascular membranes in 121
N
Neovascularization in age-related macular degeneration, quantification of 5-6, 6
Nerve fiber layer (NFL) infarct 160
Nonexudative choroidal neovascularization 83, 85-88, 98, 99
classification 86
etiology 88
management 87-88
natural history 87
nature of 86
OCT angiography features 86, 87
as precursor to exudation 87
treatment-naïve 89, 90
Nonexudative neovascular AMD 55
Nonproliferative diabetic retinopathy (NPDR) 131-133
early 133136, 138142
O
Optical coherence tomographic angiography (OCTA) 3, 13, 131, 133-136, 145, 147, 149, 150152, 156, 159, 186, 190
advantages 13
artifacts 4-5, 5, 6, 13-16
challenges and improvement scope 13-16
clinical applications 6-7
cross-sectional 3
decorrelation value and flow velocity 3
en face 3
flow index 5
in IRD 192-194
microaneurysms on 132
nonperfusion/capillary dropout area 5
in nonproliferative diabetic retinopathy 131
projection-resolved 4
report writing 215-218
retinal plexuses and segmentation boundaries 4, 4
speckle pattern and flow signal 3
thresholded 9
unthresholded 9
vessel area density 5
vessel length density 5
Optical coherence tomography (OCT) 3, 51, 131, 133-136, 159, 173, 198, 209 in IRD 190-192, 191192
Optical coherence topography (OCT) 183
Optic disk 30
Optic nerve head (ONH) 195
Optic neuritis (ON) 209
Optic neuropathy, assessment 196
P
Pachychoroid neovasculopathy (PNV) 113
Pachydrusen 40, 41, 43
Paracentral acute middle maculopathy (PAMM) 159, 161, 163, 166
PCV see Polypoidal choroidal vasculopathy (PCV)
Photodynamic therapy (PDT) 118
Photoreceptors 28, 29, 35, 190-191
Pigment epithelium-derived factor (PEDF) 61
Polypoidal choroidal vasculopathy (PCV) 107-111
choroid thickness 107, 108
clinical features 108
ICG angiography 108-109
management 111
OCT angiography 109-111
optical coherence tomography 109, 109111
pathophysiology 107-108
Polypoidal choroidal vasculopathy (PCV) 113
Posterior vitreous detachment (PVD) 183
Primary glaucoma 196
classification 111
Projection artifacts 4, 5, 10, 13
effect on choroidal neovascularization 13, 15
projection-resolved OCTA approach 13-14, 15
slab subtraction 13, 15
Projection-resolved OCTA (PR-OCTA) 4, 4, 13-14
healthy eye 14
Proliferative diabetic retinopathy 131, 133-136, 142
in pregnant patient 143
Pseudovitelliform macular degeneration 177-178
Q
Quantitative assessment 19-21
flow area 19, 19, 20
flow density map 19, 21, 21
flow speed 21
nonflow area 19, 20
vascular dropout area 19
R
Radial peripapillary capillary plexus (RPCP) 159, 166
Radial peripapillary capillary (RPC) 198
Ranibizumab 99, 101
Reticular pseudodrusen 41, 41-42
Retina
blood-retinal barrier 23-24
Bruch's membrane 29
choroid 30, 30
deep vascular network 31
framework 25, 25
horizontal scaffold 27-28
inner blood-retinal barrier 23
inner retina 27, 28
leakage from retinal vessels 24
Müller cells and Henle fibers 25, 26
normal retinal vasculature anatomy 24, 31-32, 3133
OCT and OCT angiography 24, 24-25, 25
optic disk 30
outer blood-retinal barrier 23-24
outer retina 27-28
photoreceptors, cones and rods 28, 29
pigment epithelium 29
sclera 30, 30
superficial vessels 31
vertical scaffold 25, 27, 28
Retinal angiomatous proliferations 80-81, 81
Retinal artery occlusions 154-155
Retinal capillary ischemia 167
Retinal pigment epithelium (RPE) 23, 29, 39
Retinal plexuses 4, 4
Retinal nerve fiber layer (RNFL) 185, 186187, 191-192, 209
Retinitis pigmentosa 189
S
Sclera 30, 30
Shadow artifacts 4-5, 6
Signal reduction artifacts 14-15, 16
Split-spectrum amplitude-decorrelation angiography (SSADA) 3
Stargardt disease 174-176, 175176
Subretinal drusenoid deposits (SDD) 41, 43
Superficial capillary plexus (SCP) 159, 166
Suprachoroidal space 30
T
Three-dimensional (3D) functional cube 10
Type II membranoproliferative glomerulonephritis 42-43, 43
V
Vascular endothelial growth factor (VEGF) 61
Vascularized drusen 42-43, 51-54, 53
Venous occlusions 145
Virchow's triad 145
Vision loss see Age-related macular degeneration (AMD)
Vitreomacular adhesion (VMA) 183
Vitreomacular traction (VMT) 183
Vitreoretinal interface (VMI) 183
W
White dot syndromes 104
X
X-linked retinoschisis 189
Z
Ziv-aflibercept 101
Zonulae occludentes 23-24
×
Chapter Notes

Save Clear


Technology principles and terminologyCHAPTER 1

David Huang,
Yali Jia
 
Structural optical coherence tomography
Conventional structural optical coherence tomography (OCT) is based on reflectance signal backscattered from tissue structures. The reflectance signal provides information on variations in intrinsic tissue reflectivity on a microstructural level, but is also affected by shadowing, pupil vignetting, media opacity, defocus, incidence angle, and other factors that affect the signal strength.
 
Optical coherence tomographic angiography
Optical coherence tomographic angiography (OCTA) methodology has evolved over the past decade. It is a functional extension of OCT, which allows for the visualization of both transverse and axial flow in blood vessels down to the capillary level. OCTA images display flow signal instead of reflectance signal. The flow signal is computed based on the variation of the speckle pattern between a series of consecutive OCT B-scans. The speckle pattern could be analyzed in terms of amplitude, phase, or complex signals.
 
Split-spectrum amplitude-decorrelation angiography
Recognising that speckle patterns in different spectral (wavelength) bands contain independent flow information, the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm1 spectrally splits each B-scan into multiple image frames for the purpose of flow signal calculation. SSADA has been show to improve the signal-to-noise ratio of flow detection by up to a factor of 4, using only 2 consecutive B-scans at each location to obtain high-quality angiograms.2
 
Relationship between decorrelation and velocity
Optical coherence tomographic angiography is sensitive to both axial and transverse flow, with a slightly higher sensitivity for the axial component. The decorrelation value increases monotonically with higher flow velocity. The relationship is nonlinear, with the decorrelation value reaching an upper limit beyond a saturation velocity. For the typical OCTA scan pattern, the inter-B-scan time ranges between 2 and 10 milliseconds, and saturation occurs in larger retinal and choroidal vessels.3 Even in capillaries, it is difficult to measure flow velocity using OCTA because the OCT beam's focal spot diameters are typically larger than the capillary width, causing the decorrelation value to vary with capillary width as well as flow velocity.
 
Cross-sectional and en face OCTA
Optical coherence tomographic angiography data takes the form of 3-dimensional (3D) volumes containing both reflectance and flow signals. This could be display in cross sections or en face slabs. Cross-sectional OCTA typically displays vascular flow in colour and nonvascular reflectance in grey scale. En face OCTA is usually generated by maximum flow projection, where the highest flow signal value over the axial range of the slab is used for display. The slabs are based on tissue boundaries identified by image segmentation software. They should ideally enclose a single plexus or several adjacent plexuses. Slabs could 4also be designed to optimize the detection of abnormal blood vessels in normally avascular layers.
 
Retinal plexuses
Projection-resolved OCTA1 shows there are up to four retinal plexuses (depending on location), which could be organized into two complexes (Figure 1). The boundary between the superficial and deep vascular plexuses lies in the middle of the inner plexiform layer (IPL). The earliest OCTA software incorrectly divided the retinal circulation into the superficial and deep plexuses at the junction between the IPL and the inner nuclear layer (INL), which would split the IPL and cause vessel density measurements to be highly sensitive to segmentation errors. The correct segmentation boundaries should be used going forward.
 
OCTA artifacts
Bulk motion causes artifactual flow signal that appears as bright line artifacts on en face OCTA. Bulk motion artifacts could be reduced using real-time tracking during acquisition,4,5 post-processing registration,6 and post-processing subtraction algorithms (Figures 2a to c).7 Flow projection artifacts (Figures 3a to c) are the result of flickering shadows cast by flowing blood in superficial vasculature that causes reflectance variations in deeper layers, which are then detected as a flow signal by the OCTA algorithm. The artifact manifests as tails below blood vessel on cross-sectional OCTA and the replication of superficial vascular pattern on en face OCTA of deeper slabs. Projection-resolved OCTA (PR-OCTA) uses a post-processing algorithm to resolve the ambiguity between flow signal due to in-situ flow (real vessels) and projected flow, thereby removing tails and providing clean visualization of vessels in deeper slabs.8 The OCTA flow signal is also dependent on reflectance signal strength on a log-linear fashion7 and thus vessel density measured from OCTA images with low signal strength could be artifactually decreased, unless compensation were made.9 Shadows from iris vignetting, cataract, and vitreous floaters could cause artifactual retinal and choroidal perfusion defects on OCTA.
zoom view
Figure 1: Anatomic localization of vascular plexuses in the human retina in the macula, and current and proposed optical coherence tomography angiography segmentation boundaries. Cross-sectional projection-resolved optical coherence tomography angiograms (PR-OCTA) of a normal eye. Flow signals (purple for retinal and red for choroidal blood flow) were overlaid on reflectance signal (grey scale).
The ICP exists between the IPL and INL. The DCP exists between the INL and OPL. The GCLP/ICP boundary lies in the middle of the IPL and the ICP/DCP boundary lies in the middle of the INL.
(ILM, inner limiting membrane; NFL, nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; NFLP, NFL plexus; GCLP, GCL plexus; ICP, intermediate capillary plexus; DCP, deep capillary plexus; SVC, superficial vascular complex; DVC, deep vascular complex)
5
zoom view
Figure 2: Examples of bulk motion artifacts. (a) En face inner retinal angiogram. Two bright lines in the image are the result of microsaccades (green arrows), disrupting vessel continuity. (b) Typical cross-sectional angiogram [from the green, dotted line in panel (a) without motion artifact]. (c) Cross-sectional angiogram at the position of the larger microsaccade shows high flow signal at all reflective structures.
zoom view
Figure 3: Examples of projection artifacts. (a) Cross-sectional angiogram showing tails trailing beneath vessels (green arrows). (b) Inner retinal angiogram. (c) Outer retinal angiogram shows projection of the inner retinal vasculature.
And shadows from drusens could cause artifactual choroidal defects on OCTA (Figures 4a to c). Care should be taken to distinguish capillary dropout from shadow artifacts.
 
OCTA parameters quantifying perfusion and ischemia
The flow index is calculated as the average flow signal value in the region of interest on an en face OCTA.10 The vessel area density is calculated as the percentage area occupied by vessels in the selected region.11 The vessel length density is the length of the vascular network divided by the area of interest in units of mm-1.12 It is calculated from skeletonized en face OCTA. The avascular area or nonflow area sums abnormally large gaps between flow pixels on an en face angiogram.13 Nonperfusion or capillary dropout area refers to an avascular area that should normally be vascular.14,15 For example, on an OCT angiogram of the macula, any retinal avascular area outside of the FAZ is considered retinal nonperfusion area.
 
Quantification of neovascularization
In proliferative diabetic retinopathy, neovascular membrane is measured in the preretinal vitreous slab. In age-related macular degeneration, neovascularization is measured in the outer retinal slab after the removal of projection 6artifacts. On the en face angiogram, lesion or membrane area measures the area occupied by both the flow pixels (vessels) and the intervening nonflow pixels (fibrous tissue).16 The vessel area only counts the flow pixels (Figures 5a to c).17
zoom view
Figure 4: Examples of shadow artifacts. (a) Cross-sectional angiogram showing shadow artifacts caused by drusens (green arrows). (b) Inner retinal angiogram. (c) Choriocapillaris angiogram shows artifactual flow defects (black area in the middle).
zoom view
Figures 5: An example to show the quantification on neovascularization in age-related macular degeneration. (a) Choroidal neovascularization (CNV, yellow) overlaid by inner retinal vasculature (purple). (b) CNV membrane area (white) delineated automatically. (c) CNV vessel area showing flow pixels only.
 
Optovue angiovue technology
The AngioVue OCTA system Avanti (Optovue, Inc., Freemont, CA) is a high-speed (70 kHz) spectral-domain OCT system. Using the efficient SSADA algorithm, each standard OCTA volume is acquired in 3 seconds. Two image volumes are registered and merged using the patented motion correction technology (MCT) to minimise motion artifacts and improve image quality.6,18 The AngioAnalytics software maps and measures vessel density and nonflow area to measure ischemia, and vessel area to quantify neovascularization. Video tracking and high-definition (400 × 400) OCTA have been recently added to further improve image quality.
 
Clinical applications of OCTA technology
Optical coherence tomographic angiography uses intrinsic motion contrast to detect flow, and therefore does not require injection of a contrast agent like conventional fluorescein angiography (FA). The noninvasive nature of OCTA allows for routine use to detect disease and monitor treatment efficacy. Therefore, OCTA is likely 7to be used more than FA ever was. OCTA does not detect dye leakage or staining, therefore the recognition of abnormal vessels such as retinal or choroidal neovascularization is based on their distinct patterns and occurrence in normally nonvascular layers. Because OCTA is 3D, it is possible to separately visualise retinal vascular plexuses and choroidal layers by en face projection of segmented slabs. In diabetic retinopathy, retinal venous occlusion, and other retinal vascular diseases, OCTA is used to detect and quantify retinal neovascularization and ischemia (increased avascular area and decrease vessel density).19 In age-related macular degeneration, inherited retinal degenerations, and other outer retina/choroidal diseases, OCTA is used to detect and quantify choroidal neovascularization and choriocapillary defects.11,20,21 In glaucoma and other optic neuropathies, OCTA is used to detect decreased perfusion in the optic disc, peripapillary retina and choroid, and macular ganglion cell complex.22-24
References
  1. Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express 2012;20:4710–4725.
  1. Gao SS, Liu G, Huang D, et al. Optimization of the split-spectrum amplitude-decorrelation angiography algorithm on a spectral optical coherence tomography system. Opt Lett 2015;40:2305–2308.
  1. Su JP, Chandwani R, Gao SS, et al. Calibration of optical coherence tomography angiography with a microfluidic chip. J Biomed Opt 2016;21:86015.
  1. Braaf B, Vienola KV, Sheehy CK, et al. Real-time eye motion correction in phase-resolved OCT angiography with tracking SLO. Biomedical optics express 2013;4:51–65.
  1. Zhang Q, Huang Y, Zhang T, et al. Wide-field imaging of retinal vasculature using optical coherence tomography-based microangiography provided by motion tracking. J Biomed Opt 2015;20:066008.
  1. Kraus MF, Potsaid B, Mayer MA, et al. Motion correction in optical coherence tomography volumes on a per A-scan basis using orthogonal scan patterns. Biomed Opt Express 2012;3:1182–1199.
  1. Camino A, Jia Y, Liu G, et al. Regression-based algorithm for bulk motion subtraction in optical coherence tomography angiography. Biomedical optics express 2017;8:3053–3066.
  1. Zhang M, Hwang TS, Campbell JP, et al. Projection-resolved optical coherence tomographic angiography. Biomed Opt Express 2016;7:816–828.
  1. Gao SS, Jia Y, Liu L, et al. Compensation for Reflectance Variation in Vessel Density Quantification by Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sci 2016;57:4485–4492.
  1. Jia Y, Morrison JC, Tokayer J, et al. Quantitative OCT angiography of optic nerve head blood flow. Biomed Opt Express 2012;3:3127–137.
  1. Jia Y, Bailey ST, Hwang TS, et al. Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. Proc Natl Acad Sci USA 2015;112:E2395–2402.
  1. Gao SS, Liu L, Bailey ST, et al. Quantification of choroidal neovascularization vessel length using optical coherence tomography angiography. J Biomed Opt 2016;21:076010.
  1. Hwang TS, Gao SS, Liu L, et al. Automated Quantification of Capillary Nonperfusion Using Optical Coherence Tomography Angiography in Diabetic Retinopathy. JAMA Ophthalmol 2016;134:367–73.
  1. Zhang M, Hwang TS, Dongye C, et al. Automated Quantification of Nonperfusion in Three Retinal Plexuses Using Projection-Resolved Optical Coherence Tomography Angiography in Diabetic RetinopathyQuantification of Retinal Ischemia in Three Plexuses. Invest Ophthalmol Vis Sci 2016;57:5101–5106.
  1. Hwang TS, Zhang M, Bhavsar K, et al. Visualization of 3 Distinct retinal plexuses by projection-resolved optical coherence tomography angiography in diabetic retinopathy. JAMA Ophthalmol 2016;134:1411–1419.
  1. Liu L, Gao SS, Bailey ST, et al. Automated choroidal neovascularization detection algorithm for optical coherence tomography angiography. Biomed Opt Express 2015;6:3564–3576.
  1. Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 2014;121:1435–1444.
  1. Camino A, Zhang M, Gao SS, et al. Evaluation of artifact reduction in optical coherence tomography angiography with real-time tracking and motion correction technology. Biomed Opt Express 2016;7:3905–3915.
  1. Hwang TS, Hagag AM, Wang J, et al. Automated quantification of nonperfusion areas in 3 vascular plexuses with optical coherence tomography angiography in eyes of patients with diabetes. JAMA Ophthalmol 2018;136:929–936.
  1. McClintic SM, Jia Y, Huang D, et al. Optical coherence tomographic angiography of choroidal neovascularization associated with central serous chorioretinopathy. JAMA Ophthalmol 2015;133:1212–1214.

  1. 8 Patel RC, Wang J, Hwang TS, et al. Plexus-Specific Detection of Retinal Vascular Pathologic Conditions with Projection-Resolved OCT Angiography. Ophthalmol Retina 2018;2:816–826.
  1. Liu L, Jia Y, Takusagawa HL, et al. Optical coherence tomography angiography of the peripapillary retina in glaucoma. JAMA Ophthalmol 2015;133:1045–1052.
  1. Jia Y, Wei E, Wang X, et al. Optical Coherence Tomography Angiography of Optic Disc Perfusion in Glaucoma. Ophthalmology 2014;121:1322–1332.
  1. Takusagawa HL, Liu L, Ma KN, et al. Projection-Resolved Optical Coherence Tomography Angiography of Macular Retinal Circulation in Glaucoma. Ophthalmol 2017;124:1589–1599.